{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:57:36Z","timestamp":1782863856635,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2024,4,20]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n<jats:title>Introduction\/objectives<\/jats:title>\n<jats:p>The use of non-occupational post-exposure prophylaxis (nPEP) emerges as a strategic intervention to reduce HIV infection risk following sexual encounters in our setting. Notwithstanding, there is a scarcity of contemporary data regarding adherence to this treatment, its effectiveness and tolerance. Our study aims to delve into these factors among individuals who have resorted to nPEP after high-risk sexual encounters.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective observational study of cases administered nPEP for HIV from 1 January 2018 to 31 December 2021 at a tertiary hospital in Madrid. The study included all adults over 18 years who sought care at the emergency department of the Fundaci\u00f3n Jim\u00e9nez D\u00edaz Hospital following a risky sexual encounter and were subsequently recommended HIV nPEP treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>878 individuals received nPEP for HIV and underwent initial serological tests. Of these, 621 had comprehensive follow-ups. The prescribed regimen for all was raltegravir (RAL) 1200 mg combined with tenofovir\/emtricitabine (TDF\/FTC) 245\/200 mg daily for 28 days. The study revealed a 1.1% rate (n=10) of previously undetected infection and a 0.16% (n=1) failure rate of nPEP. Regarding regimen tolerability, 5.6% (n=35) experienced symptoms linked to the treatment, yet none necessitated discontinuation of the regimen. On the contrary, six per cent (n=53) reported symptoms consistent with an STI during one of the medical visits; specifically, 4.4% had urethritis, and 1.6% had proctitis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>nPEP with RAL\/TDF\/FTC demonstrates high efficacy and safety, contingent on proper adherence. There is an observed increase in STI prevalence in this cohort, with nearly half of the participants not engaging in appropriate follow-up after initiating nPEP.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/sextrans-2024-056109","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:15:15Z","timestamp":1715667315000},"page":"231-235","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics and rates of infection by HIV in people receiving non-occupational post-exposure prophylaxis (nPEP) against HIV"],"prefix":"10.1136","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-8224","authenticated-orcid":false,"given":"Irene","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"L\u00f3pez de las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Calpena","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Prieto-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aws","family":"Waleed Al-Hayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Izuzquiza","family":"Suarez-Inclan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Lumbreras","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Quesada","family":"Luengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elia Asensi","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bernal Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Asensio","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Soler","family":"Bonafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bravo Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hern\u00e1ndez-Segurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-8358","authenticated-orcid":false,"given":"Alfonso","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2024062021351729000_100.4.231.1","unstructured":"Joint United Nations Programme on HIV\/AIDS(UNAIDS) . global report: UNAIDS report on the global AIDS epidemic 2013. 2013. Available: http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2013\/gr20 13\/UNAIDS Global Report 2013 en.pdf"},{"key":"2024062021351729000_100.4.231.2","unstructured":"Unidad de vigilancia de VIH I y hepatitis . Vigilancia Epidemiol\u00f3gica del VIH Y Sida en Espa\u00f1a 2021: Sistemade Informaci\u00f3n Sobre Nuevos Diagn\u00f3sticos de VIH Y Registro Nacional de Casos de Sida Centro Nacional de Epidemiolog\u00eda. Instituto de Salud Carlos III\/ Divisi\u00f3n de control de VIH, ITS, Hepati. 2022."},{"key":"2024062021351729000_100.4.231.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421303"},{"key":"2024062021351729000_100.4.231.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0"},{"key":"2024062021351729000_100.4.231.5","unstructured":"La P , Vih AL . GU\u00edA DE ACTUACI\u00f3N PROFILAXIS POST-EXPOSICI\u00f3N NO OCUPACIONAL. Available: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/docs\/guia_actuacion_profilaxis.pdf [Accessed 28 Apr 2021]."},{"key":"2024062021351729000_100.4.231.6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eimc.2011.05.006","article-title":"Prevenci\u00f3n de la Transmisi\u00f3n del VIH (vertical, Ocupacional Y no Ocupacional)","volume":"29","author":"Azkune","year":"2011","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"2024062021351729000_100.4.231.7","unstructured":"Transmission of HIV Possibly Associated with Exposure of Mucous Membrane to Contaminated Blood, Available: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00048364.htm [Accessed 29 Apr 2021]."},{"key":"2024062021351729000_100.4.231.8","unstructured":"Hernando V , Sim\u00f3n L , Ruiz-Alguer\u00f3 M , et al . Vigilancia Epidemiol\u00f3gica de Las Infecciones de Transmisi\u00f3n sexual en Espa\u00f1a. In: Cent Nac Epidemiol Inst Salud Carlos III\/Divisi\u00f3n Control VIH, ITS, Hepat virales y Tuberc. 2023: 1\u201339."},{"key":"2024062021351729000_100.4.231.9","unstructured":"Sanidad MDE . Plan de Prevencion Y control. In: Ministerio de sanidad. 2023."},{"key":"2024062021351729000_100.4.231.10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.20.9771-9775.2000"},{"key":"2024062021351729000_100.4.231.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811123392001"},{"key":"2024062021351729000_100.4.231.12","doi-asserted-by":"publisher","DOI":"10.1086\/320166"},{"key":"2024062021351729000_100.4.231.13","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404150-00010"},{"key":"2024062021351729000_100.4.231.14","unstructured":"Shah SS . The medical care criteria committee with. NYSDOH AI diagnosis and management of HIV-2 in adults. 2020. Available: https:\/\/cdn.hivguidelines.org\/wp-content\/uploads\/20201005110222\/NYSDOH-AI-Diagnosis-and-Management-of-HIV-2-in-Adults_10-5-2020_HG.pdf [Accessed 28 Apr 2021]."},{"key":"2024062021351729000_100.4.231.15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/01.olq.0000237838.43716.ee","article-title":"Trends in HIV Postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004","volume":"34","author":"Sonder","year":"2007","journal-title":"Sex Transm Dis"},{"key":"2024062021351729000_100.4.231.16","doi-asserted-by":"publisher","DOI":"10.1086\/672271"},{"key":"2024062021351729000_100.4.231.17","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12075"},{"key":"2024062021351729000_100.4.231.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04331-2"},{"key":"2024062021351729000_100.4.231.19","unstructured":"HF G , MS S , CA B , et al . Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International antiviral society-USA panel. JAMA 2016;316."},{"key":"2024062021351729000_100.4.231.20","unstructured":"Direcci\u00f3n General de Salud P\u00fablica Calidad e Innovaci\u00f3n . Recomendaciones En Personas Sin Sospecha de Infecci\u00f3n Por VIH o SIDA. Gu\u00eda Recom Para El Diagn\u00f3stico Precoz Del VIH En El \u00c1mbito Sanit.2014:28\u201332.Available: http:\/\/www.msssi.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/docs\/GuiaRecomendacionesDiagnosticoPrecozVIH.pdf"},{"key":"2024062021351729000_100.4.231.21","unstructured":"Grupo de trabajo sobre ITS . Madrid. Infecciones de Transmisi\u00f3n Sexual: Diagn\u00f3stico, Tratamiento, Prevenci\u00f3n y Control.2011. Available: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/DocITS2011.pdf [accessed 23 Apr 2021]."},{"key":"2024062021351729000_100.4.231.22","first-page":"313","article-title":"Prevalencia Y Caracter\u00edsticas de Los Pacientes con Infecci\u00f3n Por virus de la Inmunodeficiencia Humana (VIH) Diagnosticados de novo en UN Servicio de Urgencias","volume":"28","author":"Pizarro Portillo","year":"2016","journal-title":"Emergencias"},{"key":"2024062021351729000_100.4.231.23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eimc.2018.03.007","article-title":"Missed opportunities in the diagnosis of human immunodeficiency virus infection in the region of Aragon. late diagnosis importance","volume":"37","author":"Gargallo-Bernad","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2024062021351729000_100.4.231.24","doi-asserted-by":"publisher","DOI":"10.1086\/497274"},{"key":"2024062021351729000_100.4.231.25","unstructured":"Dominguez KL , Smith DK , Thomas V , et al . Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV\u2014United States, 2016. Available: https:\/\/stacks.cdc.gov\/view\/cdc\/38856 [Accessed 26 May 2023]."},{"key":"2024062021351729000_100.4.231.26","unstructured":"ON POST-EXPOSURE PROPHYLAXIS FOR HIV AND THE USE OF CO-TRIMOXAZOLE PROPHYLAXIS FOR HIV-RELATED INFECTIONS AMONG ADULTS, ADOLESCENTS AND CHILDREN: RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH DECEMBER 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION, Available: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/145719\/9789241508193_eng.pdf?sequence=1 [Accessed 26 May 2023]."},{"key":"2024062021351729000_100.4.231.27","unstructured":"EAC Society . Guidelines European AIDS clinical society version 12.0. 2023. Available: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25038358"},{"key":"2024062021351729000_100.4.231.28","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824a03b8"},{"key":"2024062021351729000_100.4.231.29","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2005.014662"},{"key":"2024062021351729000_100.4.231.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211934"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2024-056109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:30:10Z","timestamp":1719257410000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2024-056109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,31]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/sextrans-2024-056109"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2024-056109","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}